IDEXX Laboratories, Inc. Logo

IDEXX Laboratories, Inc.

0J8P.L

(0.0)
Stock Price

415,54 USD

29.2% ROA

57.03% ROE

46.47x PER

Market Cap.

39.138.924.627,00 USD

61.06% DER

0% Yield

22.34% NPM

IDEXX Laboratories, Inc. Stock Analysis

IDEXX Laboratories, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

IDEXX Laboratories, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

IDEXX Laboratories, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

IDEXX Laboratories, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

IDEXX Laboratories, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

IDEXX Laboratories, Inc. Revenue
Year Revenue Growth
1991 30.500.000
1992 57.700.000 47.14%
1993 93.100.000 38.02%
1994 126.400.000 26.34%
1995 188.600.000 32.98%
1996 267.700.000 29.55%
1997 263.000.000 -1.79%
1998 319.900.000 17.79%
1999 356.200.000 10.19%
2000 367.432.000 3.06%
2001 386.081.000 4.83%
2002 412.670.000 6.44%
2003 475.992.000 13.3%
2004 549.181.000 13.33%
2005 638.095.000 13.93%
2006 739.117.000 13.67%
2007 922.555.000 19.88%
2008 1.024.030.000 9.91%
2009 1.031.633.000 0.74%
2010 1.103.392.000 6.5%
2011 1.218.689.000 9.46%
2012 1.293.338.000 5.77%
2013 1.377.058.000 6.08%
2014 1.485.807.000 7.32%
2015 1.601.892.000 7.25%
2016 1.775.423.000 9.77%
2017 1.969.058.000 9.83%
2018 2.213.242.000 11.03%
2019 2.406.908.000 8.05%
2020 2.706.655.000 11.07%
2021 3.215.360.000 15.82%
2022 3.367.324.000 4.51%
2023 3.662.108.000 8.05%
2023 3.660.953.000 -0.03%
2024 4.014.312.000 8.8%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

IDEXX Laboratories, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1991 0
1992 0 0%
1993 0 0%
1994 8.200.000 100%
1995 10.200.000 19.61%
1996 12.200.000 16.39%
1997 17.100.000 28.65%
1998 21.500.000 20.47%
1999 27.300.000 21.25%
2000 28.292.000 3.51%
2001 28.426.000 0.47%
2002 29.329.000 3.08%
2003 32.319.000 9.25%
2004 35.402.000 8.71%
2005 40.948.000 13.54%
2006 53.617.000 23.63%
2007 67.338.000 20.38%
2008 70.552.000 4.56%
2009 65.124.000 -8.33%
2010 68.597.000 5.06%
2011 76.042.000 9.79%
2012 82.014.000 7.28%
2013 88.003.000 6.81%
2014 98.263.000 10.44%
2015 99.681.000 1.42%
2016 101.122.000 1.43%
2017 109.182.000 7.38%
2018 117.863.000 7.37%
2019 133.193.000 11.51%
2020 141.249.000 5.7%
2021 161.009.000 12.27%
2022 254.820.000 36.81%
2023 191.868.000 -32.81%
2023 190.951.000 -0.48%
2024 221.800.000 13.91%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

IDEXX Laboratories, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1991 0
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 41.266.000 100%
2003 45.752.000 9.81%
2004 49.870.000 8.26%
2005 64.631.000 22.84%
2006 82.097.000 21.27%
2007 108.119.000 24.07%
2008 115.586.000 6.46%
2009 117.440.000 1.58%
2010 126.519.000 7.18%
2011 129.389.000 2.22%
2012 137.609.000 5.97%
2013 157.861.000 12.83%
2014 173.890.000 9.22%
2015 182.510.000 4.72%
2016 207.017.000 11.84%
2017 220.878.000 6.28%
2018 244.938.000 9.82%
2019 261.317.000 6.27%
2020 300.832.000 13.14%
2021 309.660.000 2.85%
2022 326.248.000 5.08%
2023 356.136.000 8.39%
2023 335.825.000 -6.05%
2024 628.972.000 46.61%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

IDEXX Laboratories, Inc. EBITDA
Year EBITDA Growth
1991 2.800.000
1992 7.600.000 63.16%
1993 16.600.000 54.22%
1994 27.200.000 38.97%
1995 34.500.000 21.16%
1996 49.100.000 29.74%
1997 37.800.000 -29.89%
1998 75.300.000 49.8%
1999 64.000.000 -17.66%
2000 72.732.000 12.01%
2001 78.781.000 7.68%
2002 85.939.000 8.33%
2003 99.170.000 13.34%
2004 126.068.000 21.34%
2005 139.248.000 9.47%
2006 157.597.000 11.64%
2007 177.283.000 11.1%
2008 172.456.000 -2.8%
2009 175.969.000 2%
2010 203.881.000 13.69%
2011 236.225.000 13.69%
2012 262.563.000 10.03%
2013 266.762.000 1.57%
2014 260.255.000 -2.5%
2015 308.124.000 15.54%
2016 350.239.000 12.02%
2017 413.028.000 15.2%
2018 491.335.000 15.94%
2019 552.846.000 11.13%
2020 694.524.000 20.4%
2021 932.028.000 25.48%
2022 898.765.000 -3.7%
2023 1.217.072.000 26.15%
2023 1.097.128.000 -10.93%
2024 1.190.860.000 7.87%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

IDEXX Laboratories, Inc. Gross Profit
Year Gross Profit Growth
1991 18.700.000
1992 36.000.000 48.06%
1993 58.900.000 38.88%
1994 77.700.000 24.2%
1995 113.400.000 31.48%
1996 164.800.000 31.19%
1997 143.200.000 -15.08%
1998 177.700.000 19.41%
1999 191.300.000 7.11%
2000 196.657.000 2.72%
2001 183.331.000 -7.27%
2002 192.725.000 4.87%
2003 230.304.000 16.32%
2004 279.017.000 17.46%
2005 322.900.000 13.59%
2006 379.529.000 14.92%
2007 463.522.000 18.12%
2008 529.766.000 12.5%
2009 526.281.000 -0.66%
2010 578.623.000 9.05%
2011 646.506.000 10.5%
2012 699.148.000 7.53%
2013 756.118.000 7.53%
2014 816.116.000 7.35%
2015 890.270.000 8.33%
2016 975.436.000 8.73%
2017 1.097.382.000 11.11%
2018 1.241.542.000 11.61%
2019 1.365.549.000 9.08%
2020 1.571.040.000 13.08%
2021 1.889.432.000 16.85%
2022 2.004.338.000 5.73%
2023 2.191.928.000 8.56%
2023 2.189.970.000 -0.09%
2024 2.483.520.000 11.82%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

IDEXX Laboratories, Inc. Net Profit
Year Net Profit Growth
1991 3.200.000
1992 4.900.000 34.69%
1993 9.700.000 49.48%
1994 13.300.000 27.07%
1995 21.500.000 38.14%
1996 32.600.000 34.05%
1997 -21.100.000 254.5%
1998 -15.200.000 -38.82%
1999 32.600.000 146.63%
2000 36.632.000 11.01%
2001 37.620.000 2.63%
2002 45.389.000 17.12%
2003 57.090.000 20.5%
2004 78.332.000 27.12%
2005 78.254.000 -0.1%
2006 93.678.000 16.46%
2007 94.014.000 0.36%
2008 116.169.000 19.07%
2009 122.225.000 4.95%
2010 141.284.000 13.49%
2011 161.786.000 12.67%
2012 178.267.000 9.25%
2013 187.800.000 5.08%
2014 181.906.000 -3.24%
2015 192.078.000 5.3%
2016 222.045.000 13.5%
2017 263.144.000 15.62%
2018 377.031.000 30.21%
2019 427.720.000 11.85%
2020 581.776.000 26.48%
2021 744.845.000 21.89%
2022 679.089.000 -9.68%
2023 848.924.000 20.01%
2023 845.042.000 -0.46%
2024 813.192.000 -3.92%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

IDEXX Laboratories, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1991 0
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 0%
2008 1 0%
2009 1 100%
2010 1 0%
2011 1 0%
2012 2 0%
2013 2 0%
2014 2 0%
2015 2 50%
2016 2 0%
2017 3 33.33%
2018 4 25%
2019 5 0%
2020 7 33.33%
2021 9 25%
2022 8 0%
2023 10 20%
2023 10 0%
2024 10 -11.11%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

IDEXX Laboratories, Inc. Free Cashflow
Year Free Cashflow Growth
1991 -5.600.000
1992 -2.400.000 -133.33%
1993 5.300.000 145.28%
1994 10.400.000 49.04%
1995 -9.100.000 214.29%
1996 -3.800.000 -139.47%
1997 -22.000.000 82.73%
1998 -2.000.000 -1000%
1999 40.200.000 104.98%
2000 12.720.000 -216.04%
2001 28.983.000 56.11%
2002 88.166.000 67.13%
2003 100.259.000 12.06%
2004 63.674.000 -57.46%
2005 92.353.000 31.05%
2006 38.471.000 -140.06%
2007 68.880.000 44.15%
2008 53.372.000 -29.06%
2009 115.875.000 53.94%
2010 139.531.000 16.95%
2011 120.479.000 -15.81%
2012 161.232.000 25.28%
2013 167.360.000 3.66%
2014 175.148.000 4.45%
2015 133.443.000 -31.25%
2016 269.784.000 50.54%
2017 296.572.000 9.03%
2018 277.148.000 -7.01%
2019 303.934.000 8.81%
2020 540.437.000 43.76%
2021 635.997.000 15.03%
2022 394.146.000 -61.36%
2023 238.339.000 -65.37%
2023 772.879.000 69.16%
2024 215.007.000 -259.47%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

IDEXX Laboratories, Inc. Operating Cashflow
Year Operating Cashflow Growth
1991 3.800.000
1992 -100.000 3900%
1993 7.400.000 101.35%
1994 14.800.000 50%
1995 6.800.000 -117.65%
1996 8.000.000 15%
1997 13.500.000 40.74%
1998 46.100.000 70.72%
1999 52.600.000 12.36%
2000 28.240.000 -86.26%
2001 46.364.000 39.09%
2002 103.253.000 55.1%
2003 117.155.000 11.87%
2004 95.379.000 -22.83%
2005 116.552.000 18.17%
2006 109.826.000 -6.12%
2007 135.124.000 18.72%
2008 143.343.000 5.73%
2009 173.718.000 17.49%
2010 178.833.000 2.86%
2011 220.700.000 18.97%
2012 230.282.000 4.16%
2013 245.996.000 6.39%
2014 235.846.000 -4.3%
2015 216.364.000 -9%
2016 334.571.000 35.33%
2017 373.276.000 10.37%
2018 400.084.000 6.7%
2019 459.158.000 12.87%
2020 648.063.000 29.15%
2021 755.546.000 14.23%
2022 542.984.000 -39.15%
2023 272.433.000 -99.31%
2023 906.510.000 69.95%
2024 248.312.000 -265.07%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

IDEXX Laboratories, Inc. Capital Expenditure
Year Capital Expenditure Growth
1991 9.400.000
1992 2.300.000 -308.7%
1993 2.100.000 -9.52%
1994 4.400.000 52.27%
1995 15.900.000 72.33%
1996 11.800.000 -34.75%
1997 35.500.000 66.76%
1998 48.100.000 26.2%
1999 12.400.000 -287.9%
2000 15.520.000 20.1%
2001 17.381.000 10.71%
2002 15.087.000 -15.21%
2003 16.896.000 10.71%
2004 31.705.000 46.71%
2005 24.199.000 -31.02%
2006 71.355.000 66.09%
2007 66.244.000 -7.72%
2008 89.971.000 26.37%
2009 57.843.000 -55.54%
2010 39.302.000 -47.18%
2011 100.221.000 60.78%
2012 69.050.000 -45.14%
2013 78.636.000 12.19%
2014 60.698.000 -29.55%
2015 82.921.000 26.8%
2016 64.787.000 -27.99%
2017 76.704.000 15.54%
2018 122.936.000 37.61%
2019 155.224.000 20.8%
2020 107.626.000 -44.23%
2021 119.549.000 9.97%
2022 148.838.000 19.68%
2023 34.094.000 -336.55%
2023 133.631.000 74.49%
2024 33.305.000 -301.23%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

IDEXX Laboratories, Inc. Equity
Year Equity Growth
1991 31.500.000
1992 70.400.000 55.26%
1993 83.600.000 15.79%
1994 99.800.000 16.23%
1995 279.100.000 64.24%
1996 322.700.000 13.51%
1997 302.700.000 -6.61%
1998 307.800.000 1.66%
1999 284.300.000 -8.27%
2000 261.747.000 -8.62%
2001 301.730.000 13.25%
2002 340.973.000 11.51%
2003 413.292.000 17.5%
2004 397.660.000 -3.93%
2005 369.310.000 -7.68%
2006 409.861.000 9.89%
2007 438.323.000 6.49%
2008 438.194.000 -0.03%
2009 514.579.000 14.84%
2010 574.281.000 10.4%
2011 539.593.000 -6.43%
2012 636.257.000 15.19%
2013 518.214.000 -22.78%
2014 117.589.000 -340.7%
2015 -83.995.000 240%
2016 -108.213.000 22.38%
2017 -53.842.000 -100.98%
2018 -9.233.000 -483.15%
2019 177.825.000 105.19%
2020 632.795.000 71.9%
2021 689.992.000 8.29%
2022 608.737.000 -13.35%
2023 1.297.407.000 53.08%
2023 1.484.530.000 12.6%
2024 1.580.253.000 6.06%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

IDEXX Laboratories, Inc. Assets
Year Assets Growth
1991 38.100.000
1992 79.700.000 52.2%
1993 98.000.000 18.67%
1994 121.700.000 19.47%
1995 312.500.000 61.06%
1996 373.900.000 16.42%
1997 377.000.000 0.82%
1998 390.500.000 3.46%
1999 360.200.000 -8.41%
2000 335.796.000 -7.27%
2001 373.107.000 10%
2002 416.652.000 10.45%
2003 521.875.000 20.16%
2004 514.237.000 -1.49%
2005 490.676.000 -4.8%
2006 559.560.000 12.31%
2007 702.179.000 20.31%
2008 765.437.000 8.26%
2009 808.527.000 5.33%
2010 897.144.000 9.88%
2011 1.030.814.000 12.97%
2012 1.103.602.000 6.6%
2013 1.230.516.000 10.31%
2014 1.384.211.000 11.1%
2015 1.474.993.000 6.15%
2016 1.530.704.000 3.64%
2017 1.713.416.000 10.66%
2018 1.537.349.000 -11.45%
2019 1.832.475.000 16.11%
2020 2.294.561.000 20.14%
2021 2.437.203.000 5.85%
2022 2.746.765.000 11.27%
2023 3.086.404.000 11%
2023 3.259.925.000 5.32%
2024 3.414.867.000 4.54%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

IDEXX Laboratories, Inc. Liabilities
Year Liabilities Growth
1991 6.600.000
1992 9.300.000 29.03%
1993 14.400.000 35.42%
1994 21.900.000 34.25%
1995 33.400.000 34.43%
1996 51.200.000 34.77%
1997 74.300.000 31.09%
1998 82.700.000 10.16%
1999 75.900.000 -8.96%
2000 74.049.000 -2.5%
2001 71.377.000 -3.74%
2002 75.679.000 5.68%
2003 108.583.000 30.3%
2004 116.577.000 6.86%
2005 121.366.000 3.95%
2006 149.699.000 18.93%
2007 263.856.000 43.26%
2008 327.243.000 19.37%
2009 293.948.000 -11.33%
2010 322.863.000 8.96%
2011 491.221.000 34.27%
2012 467.345.000 -5.11%
2013 712.302.000 34.39%
2014 1.266.622.000 43.76%
2015 1.558.988.000 18.75%
2016 1.638.917.000 4.88%
2017 1.767.258.000 7.26%
2018 1.546.582.000 -14.27%
2019 1.654.650.000 6.53%
2020 1.661.766.000 0.43%
2021 1.747.211.000 4.89%
2022 2.138.028.000 18.28%
2023 1.788.997.000 -19.51%
2023 1.775.395.000 -0.77%
2024 1.834.614.000 3.23%

IDEXX Laboratories, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
45.8
Net Income per Share
10.23
Price to Earning Ratio
46.47x
Price To Sales Ratio
10.34x
POCF Ratio
40.54
PFCF Ratio
46.65
Price to Book Ratio
24.87
EV to Sales
10.52
EV Over EBITDA
34.57
EV to Operating CashFlow
41.07
EV to FreeCashFlow
47.45
Earnings Yield
0.02
FreeCashFlow Yield
0.02
Market Cap
39,14 Bil.
Enterprise Value
39,81 Bil.
Graham Number
66.36
Graham NetNet
-9.52

Income Statement Metrics

Net Income per Share
10.23
Income Quality
1.15
ROE
0.57
Return On Assets
0.25
Return On Capital Employed
0.47
Net Income per EBT
0.8
EBT Per Ebit
0.98
Ebit per Revenue
0.29
Effective Tax Rate
0.2

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.6
Operating Profit Margin
0.29
Pretax Profit Margin
0.28
Net Profit Margin
0.22

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
11.73
Free CashFlow per Share
10.15
Capex to Operating CashFlow
0.13
Capex to Revenue
0.03
Capex to Depreciation
1.08
Return on Invested Capital
0.34
Return on Tangible Assets
0.29
Days Sales Outstanding
58.66
Days Payables Outstanding
28.65
Days of Inventory on Hand
92.66
Receivables Turnover
6.22
Payables Turnover
12.74
Inventory Turnover
3.94
Capex per Share
1.58

Balance Sheet

Cash per Share
4,86
Book Value per Share
19,12
Tangible Book Value per Share
12.85
Shareholders Equity per Share
19.12
Interest Debt per Share
11.71
Debt to Equity
0.61
Debt to Assets
0.28
Net Debt to EBITDA
0.58
Current Ratio
1.32
Tangible Asset Value
1,06 Bil.
Net Current Asset Value
-0,37 Bil.
Invested Capital
1698821000
Working Capital
0,35 Bil.
Intangibles to Total Assets
0.15
Average Receivables
0,59 Bil.
Average Payables
0,12 Bil.
Average Inventory
385278500
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

IDEXX Laboratories, Inc. Dividends
Year Dividends Growth

IDEXX Laboratories, Inc. Profile

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

CEO
Mr. Jonathan J. Mazelsky
Employee
11.000
Address
One IDEXX Drive
Westbrook, 04092

IDEXX Laboratories, Inc. Executives & BODs

IDEXX Laboratories, Inc. Executives & BODs
# Name Age
1 Mr. Michael P. Johnson
Executive Vice President & Chief Human Resources Officer
70
2 Mr. George J. Fennell
Senior Vice President & Chief Revenue Officer
70
3 Mr. Jeffery D. Chadbourne
Senior Vice President of Commercial Finance & Sales Operations
70
4 Mr. Jonathan J. Mazelsky
President, Chief Executive Officer & Director
70
5 Mr. Ken Grady
Senior Vice President & Chief Information Officer
70
6 Ms. Sharon E. Underberg
Executive Vice President, General Counsel, & Corporate Secretary
70
7 Mr. John Hart
Senior Vice President of Global Operations
70
8 Dr. Martin Smith Ph.D.
Executive Vice President & Chief Technology Officer
70
9 Mr. Michael J. Lane
Executive Vice President and GM of Reference Laboratories & Information Technology
70
10 Mr. Brian P. McKeon
Chief Financial Officer, Executive Vice President & Treasurer
70

IDEXX Laboratories, Inc. Competitors